US eligibility and preventable cardiovascular disease events from semaglutide in type 2 diabetes
Background The SUSTAIN-6 trial showed the cardiovascular disease (CVD) benefits of semaglutide among patients with type 2 diabetes mellitus (T2DM). We estimated the US population eligibility and preventable CVD events from semaglutide. Methods US adults with T2DM were selected from the National Heal...
Gardado en:
| Principais autores: | , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
SAGE Publishing
2025-09-01
|
| Series: | Diabetes & Vascular Disease Research |
| Acceso en liña: | https://doi.org/10.1177/14791641251376551 |
| Tags: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|